Bold Moves

Unleash the power of our people

Lead the conversation

With its five-point plan, Pfizer called on all members of the innovation ecosystem to commit to working together to end the COVID-19 global health crisis.

In mid-March, as the COVID-19 pandemic began to sweep across the globe, Pfizer made five promises to help scientists more rapidly bring forward therapies and vaccines to protect humankind.

  • Sharing tools and insights: Pfizer committed to making cell-based assays, viral screening, serological assays, translational models and similarly vital tools available on an open-source platform to the broader scientific community and to sharing the data and learnings gained with other companies in real time to rapidly advance therapies and vaccines to patients.
  • Marshalling our people: Pfizer created a SWAT team of our leading virologists, biologists, chemists, clinicians, epidemiologists, vaccine experts, pharmaceutical scientists and other key experts to focus solely on addressing the pandemic.​​​​​​
  • Applying our drug development expertise: Pfizer committed to sharing our clinical development and regulatory expertise to support smaller biotech companies that may lack the experience in late-stage development and working with regulatory authorities that is necessary to advance these companies’ most promising candidates.
  • Offering our manufacturing capabilities: As one of the industry’s largest manufacturers, Pfizer committed to using any excess manufacturing capacity and to potentially shifting production to help others get these life-saving breakthroughs into the hands of patients as quickly as possible.
  • Improving future rapid response: Finally, to address future global health threats, Pfizer reached out to federal agencies including NIH, NIAID and CDC to build a cross-industry rapid response team of scientists, clinicians and technicians able to move into action immediately when future epidemics surface.

​​​​​With this five-point plan, Pfizer called on all members of the innovation ecosystem – from large pharmaceutical companies to the smallest biotech companies, from government agencies to academic institutions – to commit to working together to end this global health crisis.

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories